2 AI Healthcare Stocks to Buy Right Now
While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has…
Diversify With These Health ETFs
The FDA recently approved higher-dose version of Novo Nordisk’s NVO obesity drug Wegovy, further expanding the drug giant’s footprint in…
SuppCo launches certification to verify actives in dietary supplements
The new program complements SuppCo’s TrustScore supplement quality rating system and builds on earlier testing initiatives, which revealed…
AI breakthrough could dramatically lower the cost of drug development
Three-letter DNA “words” can decide whether a yeast cell cranks out a medicine efficiently or sputters along. The…
Marty Makary addresses staff concerns over drug voucher program
WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Tiny human heart organoids open the door to safer, faster drug discovery
Millions of people live with atrial fibrillation, a racing, uneven heartbeat that can leave you exhausted and scared.…
Brain training game shows early promise for treating chronic pain without drugs
Researchers at the University of New South Wales Sydney are testing a new way to treat chronic nerve…
Pharma’s ‘Dr. Optimistic’ is worried about the industry’s future
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
AbbVie parts ways with Calico
Unexpected uncoupling raises questions about the pace – and patience – of longevity drug discovery amid shifting pharma…